---
title: "Ventripoint Announces Closing of Third Tranche of Amended Non-Brokered Convertible Debenture Private Placement and Extension of Offering"
date: "2025-02-10 22:00:12"
summary: "(TheNewswire)Toronto, Ontario – TheNewswire - February 10, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the“Corporation”, (TSXV:VPT)announces, further to its press release dated December 17, 2024 andJanuary 20, 2025 announcing the closing of the first and secondtranches of its non-brokered private placement (see November 6, 2024, December 9, 2024, December 17,..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

(TheNewswire)




Toronto, Ontario – TheNewswire - February 10, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the“Corporation”, (TSXV:VPT)announces, further to its press release dated December 17, 2024 andJanuary 20, 2025 announcing the closing of the first and secondtranches of its non-brokered private placement (see November 6, 2024, December 9, 2024, December 17, 2024and December 20, 2024 press releases) (the“Offering”) of unsecured convertible debentures (“Debentures”) whichraised gross proceeds of $341,000 and $169,000 respectively, theclosing of the third tranche of  the Offeringwith the issuance of an additional $87,000 principal amountDebentures.

The Debentures mature on June 28, 2027. The principalamount of each $1,000 of Debenture will be convertible, at the optionof the holder, into common shares of the Corporation (“Common Share”) at aconversion price of CDN$0.10 for the first year of the term, CDN$0.15for the second year of the term and at CDN$0.25 thereafter.(the “Conversion Price”),

The Debentures bear simple interest at an annual rateof ten per cent (10%), calculated on the principal amount, with anyaccrued but unpaid interest under the Debentures due and payablesemi-annually in arrears in either cash or at the option of theCorporation 40% cash and 60% Common Shares, or 100% common shares atthe option of the holder, with the number of Common Shares beingdetermined by using the 20-day volume-weighted average price of theCommon Shares on the TSX Venture Exchange (“Exchange”) on thatdate that is five (5) days prior to the last trading day of theapplicable period.

The Debentures will convert automatically into CommonShares of the Corporation in the event the Corporations’ CommonShares closing price prior to October 20, 2026 exceeds 100% of theConversion Price on the Exchange for 5 consecutive trading days basedon volume weighted average closing price (“Automatic Conversion”).  In the event of Automatic Conversion, each Debentureholder will receive warrants (“Warrants”) to purchase that number of CommonShares as is equal to 50% of the shares issuable on conversion of theDebentures until October 20, 2026, at an exercise price of $0.28 pershare.  In the event the Common Shares of the Corporation closingprice on the Exchange exceeds $1.00 for 5 consecutive trading days,based on volume weighted average price, the Corporation will have theright to accelerate the expiry of the Warrants to ten (10) days.

The Corporation will use the proceeds of the Offeringto fund operational costs related sales and marketing, additional keypersonnel, and for general working capital purposes.

All securities issued and issuable pursuant to theOffering will be subject to a hold period of four months plus one dayfrom the date of closing of the Offering. The Offering is subject toapproval by the Exchange.

The securities offered will not beregistered under the U.S. Securities Act of 1933, as amended, and maynot be offered or sold in the United States absent a registrationstatement or an applicable exemption from the registrationrequirements. The pressrelease shall not constitute an offer to sell or the solicitation ofan offer to buy nor shall there be any sale of the securities in anyState in which such offer, solicitation or sale would beunlawful.

About Ventripoint DiagnosticsLtd.

Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary knowledge-based reconstruction technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all of Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.

For further information, pleasecontact:

Hugh MacNaught

hmacnaught@ventripoint.com

604-671-4201

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Corporation.Although the Corporation believes that the expectations andassumptions on which such forward-looking statements and informationare based are reasonable, undue reliance should not be placed on theforward-looking statements and information because the Corporation cangive no assurance that they will prove to be correct.

Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Corporation'smost recent annual management's discussion and analysis that isavailable on the Corporation's profile on SEDAR+ at www.sedarplus.ca. Readersare cautioned that the foregoing list of factors is not exhaustive.The forward-looking statements included in this news release areexpressly qualified by this cautionary statement. The forward-lookingstatements and information contained in this news release are made asof the date hereof and the Corporation undertakes no obligation toupdate publicly or revise any forward-looking statements orinformation, whether as a result of newinformation, future events or otherwise, unless so required byapplicable securities laws.

NOT FOR DISTRIBUTION TOUNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITEDSTATES

Copyright (c) 2025 TheNewswire - All rights reserved.

[Reuters](https://www.tradingview.com/news/reuters.com,2025-02-10:newsml_Tnw6qynDf:0-ventripoint-announces-closing-of-third-tranche-of-amended-non-brokered-convertible-debenture-private-placement-and-extension-of-offering/)
